Lazertinib: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Lazertinib appears in the FDA drug-label database. Marketed as LAZCLUZE.
- Drug class
- Kinase Inhibitor (FDA established pharmacologic class)
- Mechanism of action
- Kinase Inhibitors; Cytochrome P450 3A4 Inhibitors; Breast Cancer Resistance Protein Inhibitors (as stated on the FDA label)
FDA-approved use
LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 )
Phase breakdown
Conditions being studied
| Condition | Trials |
|---|---|
| Lung cancer · Lazertinib for Lung cancer | 5 |
| Carcinoma, Non-Small-Cell Lung · Lazertinib for Carcinoma, Non-Small-Cell Lung | 3 |
| Lazertinib | 1 |
| Non-Small Cell Lung Cancer Metastatic | 1 |
Recruiting trials involving Lazertinib
- A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
- A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Common questions
Is Lazertinib FDA-approved?
Yes, marketed as LAZCLUZE.
How many recruiting trials involve Lazertinib?
5 recruiting trials across 4 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.